Agitation in dementia is one of the most common and most challenging BPSD manifestations. The clinical discipline is to address reversible contributors and non-pharmacological factors first, then deploy pharmacological treatment selectively when behavioral approaches are inadequate and the agitation produces safety concerns or substantial distress. The specific agents have meaningful evidence and meaningful side effects; the choice reflects both the clinical picture and the cost-benefit of each option.
Non-pharmacological as primary treatment. Environmental modifications — consistent routine, reduced excessive stimulation, structured meaningful activity, appropriate lighting, comfortable temperature. Caregiver communication strategies — validation rather than reality-orientation in moderate-advanced dementia, calm approach, redirection rather than confrontation. Addressing unmet needs — pain assessment (frequently missed), hunger, toileting, comfort, social engagement. Music therapy has substantive evidence. Aromatherapy has some evidence. Pet therapy, art therapy, structured activities matched to patient's previous interests. The CMS, AGS, and APA guidelines all emphasize non-pharmacological approaches as first-line.
Citalopram has the best evidence among options. CitAD trial showed citalopram 30mg (now usually 20mg given QT concerns at higher doses in elderly) produced meaningful improvement in agitation in Alzheimer's disease. The mechanism (serotonergic) is distinct from antipsychotic sedation; the safety profile is more favorable for chronic use. The dose limitation (20mg in older adults due to QT prolongation concerns) is real. The agent is FDA-approved (off-label for agitation) and increasingly first-line pharmacological choice for agitation in dementia.
Brexpiprazole FDA-approved for AD agitation. First FDA-approved treatment specifically for agitation in Alzheimer's disease (approval 2023). 0.5-2mg daily. Evidence in Phase 3 trials demonstrating meaningful improvement. Side effects include weight gain, somnolence, akathisia. The mortality black box warning for antipsychotics in dementia applies though the agent has been characterized as a partial agonist with somewhat different profile. Reasonable consideration when citalopram is inadequate.
Other options and what to avoid. Trazodone 25-100mg for sleep-related agitation. Memantine for selected patients with agitation in moderate-severe AD. Low-dose valproate has some evidence but mixed; not first-line. Avoid: Haloperidol — high adverse effect burden in dementia, mortality risk. Benzodiazepines — paradoxical agitation possible, fall risk, cognitive cost. Diphenhydramine and anticholinergics — substantial cognitive cost, paradoxical agitation possible. The pharmacological discipline matters; the wrong agent can worsen the situation. The discipline is to engage agitation systematically — non-pharmacological first with attention to contributors and unmet needs, then specific pharmacological agents (citalopram, brexpiprazole) with evidence-based use, and integration with broader BPSD and family care.